Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.80 |
---|---|
High | 37.80 |
Low | 37.80 |
Bid | 42.69 |
Offer | 42.96 |
Previous close | 37.80 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Sep 19 2024 20:54 BST.
More ▼
Press releases
- Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
- Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
- Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet Reports Preliminary Second Quarter 2024 Revenue Results
- Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors
- Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024
- Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
More ▼